Hyperthermic intraoperative peritoneal chemotherapy and cytoreductive surgery for people with peritoneal metastases: a systematic review and cost-effectiveness analysis
Hypertherme intraoperative peritoneale Chemotherapie und zytoreduktive Chirurgie bei Menschen mit Peritonealmetastasen: systematische Übersicht und Kosteneffektivitätsanalyse
Health Technology Assessment · 2024-09 · 1-139
DOI: 10.3310/kwdg6338 ↗Auf einen Blick
Die Analyse verglich hypertherme intraoperative peritoneale Chemotherapie plus zytoreduktive Chirurgie mit Alternativen bei Peritonealmetastasen. Die Effekte waren je nach Tumorentität unterschiedlich; bei kolorektalem Karzinom gab es keinen Mortalitätsvorteil.
Fragestellung
Wie sind Nutzen, Schaden und Kosteneffektivität von hyperthermer intraoperativer peritonealer Chemotherapie plus zytoreduktiver Chirurgie bei Peritonealmetastasen aus kolorektalem, gastrischem oder Ovarialkarzinom im Vergleich zu anderen Strategien?
Methode
Systematische Übersicht, Metaanalyse und modellbasierte Cost-Utility-Analyse; Suche in MEDLINE, EMBASE, Cochrane Library, Science Citation Index, ClinicalTrials.gov und WHO ICTRP bis 14. April 2022; nur RCTs.
Ergebnisse
8 RCTs, 955 Teilnehmende in der quantitativen Analyse. Kolorektal: Mortalität HR 1,00 (95 %-KI 0,63–1,58); schwere UAW RR 1,69 (95 %-KI 1,03–2,77). Ovarial: Mortalität HR 0,73 (95 %-KI 0,57–0,93).
Einschränkungen
Individuelle Patient:innendaten waren nicht verfügbar; pro Vergleich nur wenige RCTs; wenig Daten zur gesundheitsbezogenen Lebensqualität.
Schlussfolgerung der Autor:innen
Bei kolorektalem Karzinom mit begrenzten Peritonealmetastasen sollte die Kombination nicht routinemäßig eingesetzt werden. Für Magenkarzinom besteht erhebliche Unsicherheit; bei Ovarialkarzinom mit Stadium III oder höher sollte sie routinemäßig angeboten werden.
Kernaussagen
- Kolorektal: kein Mortalitätsvorteil, aber mehr schwere UAW
- Ovarialkarzinom: geringere Gesamtmortalität unter der Kombination
- Für Magenkarzinom bleibt der Nutzen unsicher
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Systematische Übersicht in der Zeitschrift Health Technology Assessment, 2024-09. Verfasst von Kurinchi Gurusamy und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Surgery and Interventional Science, University College London, London, UK. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Peritoneal Neoplasms, Hyperthermic Intraperitoneal Chemotherapy, Cytoreduction Surgical Procedures. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 238 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Technology Assessment programme.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
We compared the relative benefits, harms and cost-effectiveness of hyperthermic intraoperative peritoneal chemotherapy + cytoreductive surgery ± systemic chemotherapy versus cytoreductive surgery ± systemic chemotherapy or systemic chemotherapy alone in people with peritoneal metastases from colorectal, gastric or ovarian cancers by a systematic review, meta-analysis and model-based cost–utility analysis.
Methods
We searched MEDLINE, EMBASE, Cochrane Library and the Science Citation Index, ClinicalTrials.gov and WHO ICTRP trial registers until 14 April 2022. We included only randomised controlled trials addressing the research objectives. We used the Cochrane risk of bias tool version 2 to assess the risk of bias in randomised controlled trials. We used the random-effects model for data synthesis when applicable. For the cost-effectiveness analysis, we performed a model-based cost–utility analysis using methods recommended by The National Institute for Health and Care Excellence.
Results
The systematic review included a total of eight randomised controlled trials (seven randomised controlled trials, 955 participants included in the quantitative analysis). All comparisons other than those for stage III or greater epithelial ovarian cancer contained only one trial, indicating the paucity of randomised controlled trials that provided data. For colorectal cancer, hyperthermic intraoperative peritoneal chemotherapy + cytoreductive surgery + systemic chemotherapy probably results in little to no difference in all-cause mortality (60.6% vs. 60.6%; hazard ratio 1.00, 95% confidence interval 0.63 to 1.58) and may increase the serious adverse event proportions compared to cytoreductive surgery ± systemic chemotherapy (25.6% vs. 15.2%; risk ratio 1.69, 95% confidence interval 1.03 to 2.77). Hyperthermic intraoperative peritoneal chemotherapy + cytoreductive surgery + systemic chemotherapy probably decreases all-cause mortality compared to fluorouracil-based systemic chemotherapy alone (40.8% vs. 60.8%; hazard ratio 0.55, 95% confidence interval 0.32 to 0.95). For gastric cancer, there is high uncertainty about the effects of hyperthermic intraoperative peritoneal chemotherapy + cytoreductive surgery + systemic chemotherapy versus cytoreductive surgery + systemic chemotherapy or systemic chemotherapy alone on all-cause mortality. For stage III or greater epithelial ovarian cancer undergoing interval cytoreductive surgery, hyperthermic intraoperative peritoneal chemotherapy + cytoreductive surgery + systemic chemotherapy probably decreases all-cause mortality compared to cytoreductive surgery + systemic chemotherapy (46.3% vs. 57.4%; hazard ratio 0.73, 95% confidence interval 0.57 to 0.93). Hyperthermic intraoperative peritoneal chemotherapy + cytoreductive surgery + systemic chemotherapy may not be cost-effective versus cytoreductive surgery + systemic chemotherapy for colorectal cancer but may be cost-effective for the remaining comparisons.
Limitations
We were unable to obtain individual participant data as planned. The limited number of randomised controlled trials for each comparison and the paucity of data on health-related quality of life mean that the recommendations may change as new evidence (from trials with a low risk of bias) emerges.
Conclusions
In people with peritoneal metastases from colorectal cancer with limited peritoneal metastases and who are likely to withstand major surgery, hyperthermic intraoperative peritoneal chemotherapy + cytoreductive surgery + systemic chemotherapy should not be used in routine clinical practice ( strong recommendation ). There is considerable uncertainty as to whether hyperthermic intraoperative peritoneal chemotherapy + cytoreductive surgery + systemic chemotherapy or cytoreductive surgery + systemic chemotherapy should be offered to patients with gastric cancer and peritoneal metastases (no recommendation) . Hyperthermic intraoperative peritoneal chemotherapy + cytoreductive surgery + systemic chemotherapy should be offered routinely to women with stage III or greater epithelial ovarian cancer and metastases confined to the abdomen requiring and likely to withstand interval cytoreductive surgery after chemotherapy ( strong recommendation ). Future work More randomised controlled trials are necessary. Study registration This study is registered as PROSPERO CRD42019130504. Funding This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: 17/135/02) and is published in full in Health Technology Assessment ; Vol. 28, No. 51. See the NIHR Funding and Awards website for further award information.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Surgery and Interventional Science, University College London, London, UK.
- Department of Gynaecological Oncology, University College London NHS Foundation Trust, London, UK.
- Colorectal and Peritoneal Oncology Centre, The Christie NHS Foundation Trust, Manchester, UK.
- Institute of Cancer Sciences, University of Manchester, Manchester, UK.
ORCID-Profile: Kurinchi Gurusamy, Jeffrey Leung, Claire Vale, Danielle Roberts, Audrey Linden, Xiao Wei Tan, Priyal Taribagil, Sonam Patel, Elena Pizzo, Brian Davidson, Tim Mould, Mark Saunders, Omer Aziz, Sarah O'Dwyer
Förderung
- Health Technology Assessment programme
Zitieren
APA
Gurusamy, K., Leung, J., Vale, C., Roberts, D., Linden, A., Wei Tan, X., Taribagil, P., Patel, S., Pizzo, E., Davidson, B., Mould, T., Saunders, M., Aziz, O., & O'Dwyer, S. (2024). Hyperthermic intraoperative peritoneal chemotherapy and cytoreductive surgery for people with peritoneal metastases: a systematic review and cost-effectiveness analysis. Health Technology Assessment, 1-139. https://doi.org/10.3310/kwdg6338
Vancouver
Gurusamy K, Leung J, Vale C, Roberts D, Linden A, Wei Tan X, et al. Hyperthermic intraoperative peritoneal chemotherapy and cytoreductive surgery for people with peritoneal metastases: a systematic review and cost-effectiveness analysis. Health Technology Assessment. 2024:1-139. doi:10.3310/kwdg6338
BibTeX
@article{Gurusamy2024,
author = {Gurusamy, Kurinchi and Leung, Jeffrey and Vale, Claire and Roberts, Danielle and Linden, Audrey and Wei Tan, Xiao and Taribagil, Priyal and Patel, Sonam and Pizzo, Elena and Davidson, Brian and Mould, Tim and Saunders, Mark and Aziz, Omer and O'Dwyer, Sarah},
title = {Hyperthermic intraoperative peritoneal chemotherapy and cytoreductive surgery for people with peritoneal metastases: a systematic review and cost-effectiveness analysis},
journal = {Health Technology Assessment},
year = {2024},
pages = {1--139},
doi = {10.3310/kwdg6338}
}
EUVIMED